Jazz Pharmaceuticals (NASDAQ:JAZZ) stock drops 6% amid biopharma selloff after a $145M antitrust settlement over Xyrem ...

The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary ...

Jazz (JAZZ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Thursday, April 10, 2025. Let’s ...

April 8 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its ...

It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, ...